Ayurvedic Management of Rheumatoid Arthritis (Amavata): A Systematic Review and Meta-analysis

Abstract

Background: Rheumatoid arthritis (RA) causes persistent inflammatory joint disease, progressive disability and systemic morbidity. Amavata provides an Ayurvedic framework for a comparable symptom complex involving disturbed Agni, Ama accumulation and aggravated Vata. Management may incorporate medicines, dietary regulation, lifestyle correction and selected Panchakarma procedures; however, the reliability of the clinical evidence requires careful appraisal.
Objectives: This review examined controlled clinical research on Ayurvedic care for RA/Amavata and quantitatively summarized American College of Rheumatology 20% response (ACR20) when the published outcomes permitted comparison.
Methods: Searches of PubMed/MEDLINE, indexed evidence sources and cited bibliographies were updated to 3 August 2026. Randomized and controlled studies evaluating classical individualized care or defined Ayurvedic formulations in adults with RA were considered. Study limitations were assessed across standard risk-of-bias domains. Comparative ACR20 data were combined as risk ratios (RRs) using an inverse-variance random-effects approach. The statistical synthesis was designated exploratory because some event totals had to be reconstructed from rounded percentages.
Results: The earlier evidence base contained seven possible trials with 457 participants, although reporting quality was generally weak. Three controlled comparisons supplied sufficiently similar ACR20 outcomes for quantitative synthesis. Their pooled RR was 1.14 (95% CI 0.96–1.36; I² = 0%), and therefore did not show a statistically conclusive advantage for Ayurveda. Reported ACR20 values were 39% with RA-1 and 30% with placebo; 44%, 36% and 51% with polyherbal treatment, monoherbal treatment and hydroxychloroquine, respectively; and 100%, 86% and 82% with classical Ayurveda, methotrexate and combined treatment in a small pilot study. A separate uncontrolled investigation recorded ACR20 in 56.4% (44/78), but an increase in urinary mercury reinforced the importance of product-quality control and safety surveillance.
Conclusion: Available studies indicate possible clinical benefit, yet the evidence remains limited by small samples, dissimilar interventions and methodological weaknesses. Quantitative pooling did not prove superiority over placebo or conventional comparators. Any Ayurvedic treatment should complement—not displace—appropriate DMARD-based, treat-to-target rheumatology care and should be accompanied by objective monitoring.